GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Accumulated other comprehensive income (loss)

BeiGene (HKSE:06160) Accumulated other comprehensive income (loss) : HK$-1,030 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. BeiGene's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2024 was HK$-1,030 Mil.

BeiGene's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2023 (HK$-1,135 Mil) to Dec. 2023 (HK$-777 Mil) but then declined from Dec. 2023 (HK$-777 Mil) to Mar. 2024 (HK$-1,030 Mil).

BeiGene's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 (HK$140 Mil) to Dec. 2022 (HK$-603 Mil) and declined from Dec. 2022 (HK$-603 Mil) to Dec. 2023 (HK$-777 Mil).


BeiGene Accumulated other comprehensive income (loss) Historical Data

The historical data trend for BeiGene's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Accumulated other comprehensive income (loss) Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -62.44 53.81 139.99 -602.72 -776.65

BeiGene Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -463.18 -1,125.50 -1,134.59 -776.65 -1,029.85

BeiGene Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.


BeiGene Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of BeiGene's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (HKSE:06160) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Accumulated other comprehensive income (loss)
Traded in Other Exchanges
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Executives
Jpmorgan Chase & Co. 2502 Approved lending agent
Oyler John Victor 2101 Beneficial owner
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Baker Felix James 2201 Interest of corporation controlled by you
Baker Julian Charles 2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc 2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p. 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Amgen Inc. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene (HKSE:06160) Headlines

No Headlines